These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28873034)

  • 1. The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response.
    Mehmood A; Asad MJ; Ovais M; Zaman N; Aziz H; Irfan J; Ahmad I; Raza A
    Viral Immunol; 2017 Oct; 30(8):568-575. PubMed ID: 28873034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.
    Zaman N; Asad MJ; Raza A; Raja GK; Akhter S; Mahmood M; Mahmood RT
    Ann Saudi Med; 2014; 34(5):401-6. PubMed ID: 25827697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Inglot M; Pawlowski T; Szymczak A; Malyszczak K; Zalewska M; Radkowski M
    Postepy Hig Med Dosw (Online); 2013 Mar; 67():186-91. PubMed ID: 23619217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
    Yuan HJ; Jain M; Snow KK; Gale M; Lee WM;
    J Viral Hepat; 2010 Mar; 17(3):208-16. PubMed ID: 19656286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
    Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
    Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB; Atabay A; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
    AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the role of HCV Plus-/Minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV.
    Alborzi AM; Bamdad T; Davoodian P; Hashempoor T; Nejatizadeh AA; Moayedi J
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):173-81. PubMed ID: 26342113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
    Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
    J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
    World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
    Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.
    Papastergiou V; Skorda L; Lisgos P; Stampori M; Ntetskas G; Papakonstantinou L; Prodromidou K; Karatapanis S
    J Clin Gastroenterol; 2014 Feb; 48(2):160-5. PubMed ID: 24100748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.